Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: The VERTIS SITA2 placebo-controlled randomized study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: The VERTIS SITA2 placebo-controlled randomized study

Published:2017-10-23 Issue:3 Volume:20 Page:530-540
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Dagogo-Jack Samuel¹,Liu Jie²,Eldor Roy²,Amorin Guillermo³,Johnson Jeremy²,Hille Darcy²,Liao Yuqin⁴,Huyck Susan²,Golm Gregory²,Terra Steven G.⁵^ORCID,Mancuso James P.⁶,Engel Samuel S.²,Lauring Brett²^ORCID

Affiliation:

1. University of Tennessee Health Science Center; Memphis Tennessee

2. Merck & Co., Inc.; Kenilworth New Jersey

3. MSD Argentina; Provincia de Buenos Aires Argentina

4. MSD R&D (China) Co., Ltd.; Beijing China

5. Pfizer Inc.; Andover Massachusetts

6. Pfizer Inc.; Groton Connecticut

Funder

Merck & Co., Inc., Kenilworth, New Jersey, in collaboration with Pfizer Inc.

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/dom.13116/fullpdf

Reference32 articles.

1. Standards of medical care in diabetes - 2016;American Diabetes Association;Diabetes Care.,2016

2. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes;Drucker;Lancet.,2006

3. Sitagliptin, a DPP-4 inhibitor for the treatment of patients with type 2 diabetes: a review of recent clinical trials;Karasik;Curr Med Res Opin.,2008

4. Dipeptidyl peptidase 4 inhibition with sitagliptin: a new therapy for type 2 diabetes;Deacon;Expert Opin Investig Drugs.,2007

5. Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes;Scott;Diabetes Obes Metab.,2008

Cited by 125 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A meta‐analysis of randomized controlled studies examining the effects of sodium‐glucose co‐transporter‐2 inhibitors on peripheral artery disease and risk of amputations;Diabetes, Obesity and Metabolism;2024-09-12

2. Transporter Proteins as Therapeutic Drug Targets—With a Focus on SGLT2 Inhibitors;International Journal of Molecular Sciences;2024-06-25

3. Investigation of pharmacokinetic drug interaction between clesacostat and DGAT2 inhibitor ervogastat in healthy adult participants;Clinical and Translational Science;2024-02

4. Longitudinal efficacy of Ertugliflozin in type 2 diabetes mellitus: a meta-analysis of randomized controlled trials;Expert Opinion on Pharmacotherapy;2023-11-17

5. SGLT-2 Inhibitors: The Next-generation Treatment for Type 2 Diabetes Mellitus;Current Medicinal Chemistry;2023-10-19

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3